Abstract Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) were updated in late 2019 in light of recent intervention trials involving the use of innovative lipid-lowering ...
mong patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level of less than 55 mg per deciliter resulted in a lower risk of cardiovascular events at 3 years than ...
Intensive Lipid-Lowering in Acute Coronary Syndromes: Strike Early and Strong Patients with acute coronary syndromes (ACS) face the highest risk for recurrent cardiovascular events in the early postevent period.
As we can see from the illustration, Intensive Lipid-Lowering Therapy For Chd Risk has many fascinating aspects to explore.
The use of statins decreases the risk of recurrent events, with the benefit proportionately greater with high-intensity statins and more intensive lipid control [9, 10]. Patients with an acute coronary event are at an elevated risk of recurrent events mainly due to residual lesions in the non-infarct-related artery.
dditionally, they write that future guideline revisions should include an evidence-based recommendation for more intensive LDL-C lowering in patients with high-risk diabetes and at least one additional high-risk feature.
Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) were updated in late 2019 in light of recent intervention trials involving the use of innovative lipid-lowering agents ...
Intensive lipid-lowering was associated with a significant risk reduction of coronary heart disease and must be considered even in the non-diabetic populations.
The effect of intensive lipid lowering on coronary atheroma and clinical outcome.Conclusions Aggressive lipid lowering with atorvastatin 80 mg was both safe and effective in reducing the excess of cardiovascular events in a high-risk population with CKD and CHD.
